DHR240712C245000
- 2.76
- +1.71+162.86%
Danaher Newsroom
Danaher's Leica Microsystems Enters Research Collaboration With Stanford University for AI Microscopes
Danaher (DHR) said Thursday its subsidiary Leica Microsystems entered a research collaboration with Stanford University's Department of Bioengineering to develop AI-integrated microscopes for cancer
Express News | Danaher Launched Research Collaboration With Stanford University's Department Of Bioengineering To Combine Spatial Biology With Artificial Intelligence To Help De-risk Cancer Drug Development
Express News | Danaher Launches Beacon Research Collaboration With Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 5.49% on an annualized basis producing an average annual return of 16.45%. Currently, Danaher has a market capitalization of $1
Here's Why L1 Capital International Fund Divested Its Holdings in Danaher Corporation (DHR)
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry...
Danaher on Track for Longest Losing Streak Since January 1998 -- Data Talk
Danaher Corporation (DHR) is currently at $238.96, down $0.28 or 0.12% --Would be lowest close since April 22, 2024, when it closed at $236.08 --Currently down nine consecutive days; down 6.93% over t
Goldman Sachs Adjusts Price Target on Danaher to $225 From $220, Maintains Neutral Rating
Danaher (DHR) has an average outperform rating and a price target range of $220 to $300, according to analysts polled by Capital IQ.Price: 239.03, Change: -0.22, Percent Change: -0.09
Unusual Options Activity: BCS, DLTR and Others Attract Market Bets, BCS V/OI Ratio Reaches 69.4
EST Jul 5th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Danaher Is Maintained at Outperform by Evercore ISI Group
Danaher Is Maintained at Outperform by Evercore ISI Group
Danaher Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 7.78% Evercore ISI Group $266 → $260 Maintains Outperform 04/24/2024 20.21% Citigroup $280 → $2
Evercore Maintains Danaher(DHR.US) With Buy Rating, Maintains Target Price $260
Evercore analyst Vijay Kumar maintains $Danaher(DHR.US)$ with a buy rating, and maintains the target price at $260.According to TipRanks data, the analyst has a success rate of 47.4% and a total avera
Evercore ISI Cuts Price Target on Danaher to $260 From $266, Maintains Outperform Rating
Danaher (DHR) has an average rating of outperform and price targets ranging from $220 to $300, according to analysts polled by Capital IQ. Price: 242.50, Change: -2.01, Percent Change: -0.82
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.Investors are constantly o
Barclays Maintains Danaher(DHR.US) With Hold Rating, Maintains Target Price $270
Barclays analyst Luke Sergott maintains $Danaher(DHR.US)$ with a hold rating, and maintains the target price at $270.According to TipRanks data, the analyst has a success rate of 39.9% and a total ave
FDA Approves Danaher Unit's Rapid Test for Hepatitis C
By Paul Ziobro The Food and Drug Administration on Thursday granted marketing approval to Danaher's Cepheid unit for a rapid test for hepatitis C. The approval is for Cepheid's Xpert HCV test and Ge
FDA Grants Marketing Authorization To Cepheid For Xpert HCV Test And GeneXpert Xpress System, First Point-Of-Care Hepatitis C Test
FDA Grants Marketing Authorization To Cepheid For Xpert HCV Test And GeneXpert Xpress System, First Point-Of-Care Hepatitis C Test
Danaher To Go Ex-Dividend On June 28th, 2024 With 0.27 USD Dividend Per Share
June 26th (Eastern Time) - $Danaher(DHR.US)$ is trading ex-dividend on June 28th, 2024.Shareholders of record on June 28th, 2024 will receive 0.27 USD dividend per share on July 26th, 2024. The ex-div
Did Danaher Corporation (DHR) Get a Good Analyst Rating for Its Q1 Performance?